OCULAR THERAPEUTIX, INC
OCUL · XNASCIK 1393434fmd_1FG4PBTRVH9ZAK5TV3NXT1DXVPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 2 | 2 | 4 | 17 | 44 | 51 | 58 | 64 | 52 |
| Cost of revenue | 0 | 0 | 0 | 2 | 2 | 4 | 5 | 5 | 6 | 7 |
| Gross profit | 1 | 1 | 2 | 2 | 15 | 39 | 47 | 53 | 58 | 45 |
| Research and development | 27 | 31 | 37 | 41 | 29 | 50 | 53 | 61 | 128 | 197 |
| Selling, general and administrative | 18 | 33 | 24 | 47 | 49 | 67 | 72 | 74 | 102 | 118 |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Operating income | (43) | (62) | (59) | (86) | (63) | (78) | (79) | (82) | (172) | (270) |
| Interest expense | 2 | 2 | 2 | 6 | 7 | 7 | 7 | 11 | 14 | 12 |
| Other non-operating income (expense) | (1) | (1) | (1) | (1) | (93) | 71 | 8 | 2 | (22) | 4 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (45) | (63) | (60) | (86) | (156) | (7) | (71) | (81) | (194) | (266) |
| Net income to common shareholders | (45) | – | – | – | – | (7) | (71) | (81) | – | – |